BiPar, Singulex raise fresh funds

There are two new investment rounds to report this morning. BiPar Sciences, which is developing PARP inhibitors as novel cancer therapies, announced today that it has raised $20 million from a combination of equity capital and venture debt financing. And Singulex has closed a $19 million financing round, led by JAFCO Co., Ltd. and supported by existing investors including OrbiMed Advisors and Fisk Ventures. BiPar Release l Singulex Release